Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 5, 2013, Pages 555-561

  Barnes, Neil ^a   van Noord, Jan Arie ^b   Brindicci, Caterina ^c   Lindemann, Ludger ^d   Varoli, Guido ^c   Perpiña, Miguel ^e   Guastalla, Daniele ^c   Casula, Daniela ^c   Patel, Shishir ^c   Chanez, Pascal ^f  

^a LONDON CHEST HOSPITAL   (United Kingdom)

^b Zuyderland Medical Centre   (Netherlands)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d Allergologie+ Pneumologie Praxis   (Germany)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Asthma control; Extrafine beclometasone formoterol; Fluticasone salmeterol; Lung function

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; DISKUS; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; FOSTER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BRONCHITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS;

ASTHMA CONTROL; EXTRAFINE BECLOMETASONE/FORMOTEROL; FLUTICASONE/SALMETEROL; LUNG FUNCTION;

ADMINISTRATION, INHALATION; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PARTICLE SIZE; RESPIRATORY FUNCTION TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84882668706     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.01.011     Document Type: Article

References (37)

1. Cazzoletti L., Marcon A., Janson C., Corsico A., Jarvis D., Pin I., et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. JAllergy Clin Immunol 2007, 120(6):1360-1367. Therapy and Health Economics Group of the European Community Respiratory Health Survey.
2. 2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation. BMC Pulm Med 2011, 11:40.
3. National Asthma Education and Prevention Program Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma - summary report 2007. JAllergy Clin Immunol 2007, 120(Suppl. 5):S94-S138.
4. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31:143-178.
5. British Thoracic Society, Scottish Intercollegiate Guidelines Network British guideline on the management of asthma: a national clinical guideline June 2009.
6. ATS/ERS TASK FORCE An Official American Thoracic Society/European Respiratory Society Statement: asthma control and exacerbations. Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180(1):59-99.
7. Juniper E.F., O'Byrne P.M., Guyatt G.H., Ferrie P.J., King D.R. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999, 14:902-907.
8. Nathan R.A., Sorkness C.A., Kosinski M., Schatz M., Li J.T., Marcus P., et al. Development of the asthma control test: a survey for assessing asthma control. JAllergy Clin Immunol 2004, 113:59-65.
9. Vollmer W.M., Markson L.E., O'Connor E., Sanocki L.L., Fitterman L., Berger M., et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 1999, 160:1647-1652.
10. Boulet L.-P., Boulet V., Milot J. How should we quantify asthma control? A proposal. Chest 2002, 122:2217-2223.
11. Thomas M., Kay S., Pike J., Williams A., Rosenzweig J.R.C., Hillyer E.V., et al. The asthma control test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J 2009, 18:41-49.
12. Wallenstein G.V., Carranza-Rosenzweig J., Kosinski M., Blaisdell-Gross B., Gajria K., Jhingran P. Apsychometric comparison of three patient-based measures of asthma control. Curr Med Res Opin 2007, 23:369-377.
13. Schatz M., Sorkness C.A., Li J.T., Marcus P., Murray J.J., Nathan R.A., et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. JAllergy Clin Immunol 2006, 117:549-556.
14. Juniper E.F., Svensson K., Mörk A.C., Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005, 99:553-558.
15. Svensson K., Mörk A.C., Juniper E.F. ACQ - is five out of seven items acceptable in large clinical studies?. Qual Life Res 2003, 12:771.
16. Juniper E.F., Bousquet J., Abetz L., Bateman E.D., The Goal Committee Identifying 'well controlled' and 'not well-controlled' asthma using the asthma control questionnaire. Respir Med 2006, 100:616-621.
17. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., Pedersen S.E., GOAL Investigators Group Can guideline-defined asthma control be achieved? the gaining optimal asthma control study. Am J Respir Crit Care Med 2004, 70(8):836-884.
18. O'Byrne P.M., Bisgaard H., Godard P.P., Pistolesi M., Palmqvist M., Zhu Y., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 171(2):129-136.
19. De Backer W., Devolder A., Poli G., Acerbi D., Monno R., Herpich C., et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. JAerosol Med Pulm Drug Deliv 2010, 23(3):137-148.
20. Fabbri L.M., Nicolini G., Olivieri D., Papi A. Inhaled beclometasone/formoterol extra-fine combination in the treatment of asthma: evidence and future perspectives. Expert Opin Pharmacother 2008, 9(3):479-490.
21. Tomoshi Takeda T., Toru Oga T., Akio Niimi A., Hisako Matsumoto H., Isao Ito I., Masafumi Yamaguchi M., et al. Relationship between small airway function and health status, dyspnea and disease control in asthma. Respiration 2010, 80(2):120-126.
22. Tashkin D.P. The role of small airways inflammation in asthma. Allergy Asthma Proc 2002, 23(4):233-242.
23. Ganderton D., Lewis D., Davies R., Meakin B., Brambilla G., Church T. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002, 96:S3-S8.
24. Woodcock A., Acerbi D., Poli G. Modulite technology: pharmacodynamic and pharmacokinetic implications. Respir Med 2002, 96:S9-S15.
25. Thomas M., Price D., Chrystyn H., Lloyd A., Williams A.E., von Ziegenweidt J. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med 2009, 9:1.
26. Doyle S., Lloyd A., Williams A., Chrystyn H., Moffat M., Thomas M., et al. What happens to patients who have their asthma device switched without their consent?. Prim Care Respir J 2010, 19(2):131-139.
27. USA National Institute of Health. National Heart, Lung And Blood Institute. NHLBI/WHO workshop report: global strategy for asthma management (GINA) 2010. Available from: [accessed May 2011]. http://www.ginasthma.org.
28. Allegra L., Cremonesi G., Girbino G., Ingrassia E., Marsico S., Nicolini G., et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir Med 2012, 106(2):205-214. PRISMA (PRospectIve Study on asthMA control) Study Group.
29. Papi A., Paggiaro P., Nicolini G., Vignola A.M., Fabbri L.M. Beclometasone/formoterol vs. fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007, 62(10):11.
30. Tulic M.K., Christodoulopoulos P., Hamid Q. Small airways inflammation in asthma. Respir Res 2001, 2:333-339.
31. Contoli M., Kraft M., Hamid Q., Bousquet J., Rabe K.F., Fabbri L.M., et al. Do small airways abnormalities characterize asthma phenotypes? In search of proof. Clin Exp Allergy 2012, 42:1150-1160.
32. Anderson W.J., Zajda E., Lipworth B.J. Are we overlooking persistent small airways dysfunction in community-managed asthma?. Ann Allergy Asthma Immunol 2012, 109:185-189.
33. Usmani O.S. Treating small airways. Respiration 2012, 84:441-453.
34. Molimard M., Martinat Y., Rogeaux Y., Moyse D., Pello J.Y., Giraud V. Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. Respir Med 2005, 99:770-778.
35. Juniper E.F., Price D.B., Stampone P.A., Creemers J.P., Mol S.J., Fireman P. Clinically important improvements in asthma-specific QoL, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half thedose of extrafine beclomethasone dipropionate. Chest 2002, 121:1824-1832.
36. Huchon G., Magnussen H., Chuchalin A., Dymek L., Gonod F.B., Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009, 103:41-49.
37. 2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy Asthma Proc 2012, 33(2):140-144.